EFSD and Novo Nordisk to support diabetes research
The European Foundation for the Study of Diabetes (EFSD), a German funding agency for diabetes research and Danish healthcare company Novo Nordisk are supporting diabetes research by contributing Euro 3m over the next three years to a European research programme.
The European Foundation for the Study of Diabetes (EFSD), a German funding agency for diabetes research and Danish healthcare company Novo Nordisk are supporting diabetes research by contributing Euro 3m over the next three years to a European research programme.
The programme will support European research into understanding the cause and treatment of all forms of diabetes and applications for funding are welcomed from all non-profit institutions in Europe within any area of basic or clinical diabetes research.
"Diabetes prevalence is growing rapidly. There is, therefore, an urgent need to understand the molecular mechanisms behind this disease and its associated co-morbidities," said Peter Kurtzhals, senior vice president and head of diabetes research unit at Novo Nordisk.
"We hope this grant will support research that otherwise may not be possible, and that our improved knowledge will help guide the development of safe and effective therapies in the future."
The deadline for submission of applications is 1 April 2010 and forms are available from foundation@easd.org
Since its inception, EFSD has committed more than €62m to diabetes research in Europe. The organisation is continually striving to enhance awareness of the severity and magnitude of this disease.
